Asnis, GM, De La Garza, R (2006). Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. Journal of Clinical Gastroenterology 40, 322–335.
Baraldi, S, Hepgul, N, Mondelli, V, Pariante, CM (2012). Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review. Journal of Clinical Psychopharmacology 32, 531–543.
Dieperink, E, Ho, SB, Thuras, P, Willenbring, ML (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44, 104–112.
Dieperink, E, Leskela, J, Dieperink, ME, Evans, B, Thuras, P, Ho, SB (2008). The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics 49, 225–229.
Evon, DM, Ramcharran, D, Belle, SH, Terrault, NA, Fontana, RJ, Fried, MW (2009). Virahep-C Study Group. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. American Journal of Gastroenterology 104, 2949–2958.
Gardenier, D, Wisnivesky, J, McGinn, LK, Kronish, IM, McGinn, TG (2011). Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression. Gastroenterology Nursing 34, 102–106.
Ho, SB, Nguyen, H, Tetrick, LL, Opitz, GA, Basara, ML, Dieperink, E (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology 96, 157–164.
HPA (2011). Hepatitis C in the UK, Report. Health Protection Agency, London.
Huckans, M, Mitchell, A, Ruimy, S, Loftis, J, Hauser, P (2010). Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophrenia Bulletin 36, 165–172.
Lang, JP, Melin, P, Ouzan, D, Rotily, M, Fontanges, T, Marcellin, P, Chousterman, M, Cacoub, P; CheObs Study Group (2010). Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antiviral Therapy 15, 599–606.
Lim, C, Olson, J, Zaman, A, Phelps, J, Ingram, KD (2010). Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection. Journal of Clinical Gastroenterology 44, 141–146.
Mulder, RT, Ang, M, Chapman, B, Ross, A, Stevens, IF, Edgar, C (2000). Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. Journal of Gastroenterology and Hepatology 15, 300–303.
Neri, S, Bertino, G, Petralia, A, Giancarlo, C, Rizzotto, A, Calvagno, GS, Mauceri, B, Abate, G, Boemi, P, Di Pino, A, Ignaccolo, L, Vadala', G, Misseri, M, Maiorca, D, Mastrosimone, G, Judica, A, Palermo, F (2010). A multidisciplinary therapeutic approach for reducing the risk of psychiatric side-effects in patients with chronic hepatitis C treated with pegylated Interferon alpha and ribavirin. Journal of Clinical Gastroenterology 44, 210–217.
Pariante, CM, Landau, S, Carpiniello, B; Cagliari Group (2002). Interferon alpha-induced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine 347, 148–149.
Pariante, CM, Orrù, MG, Baita, A, Farci, MG, Carpiniello, B (1999). Treatment with interferon alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354, 131–132.
Quelhas, R, Lopes, A (2009). Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. Journal of Psychiatric Practice 15, 262–281.
Schaefer, M, Hinzpeter, A, Mohmand, A, Janssen, G, Pich, M, Schwaiger, M, Sarkar, R, Friebe, A, Heinz, A, Kluschke, M, Ziemer, M, Gutsche, J, Weich, V, Halangk, J, Berg, T (2007). Hepatitis C treatment in ‘difficult-to-treat’ psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46, 991–998.
Schaefer, M, Schmidt, F, Folwaczny, C, Lorenz, R, Martin, G, Schindlbeck, N, Heldwein, W, Soyka, M, Grunze, H, Koenig, A, Loeschke, K (2003). Adherence and mental side-effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 37, 443–451.
Schaefer, M, Schwaiger, M, Garkisch, AS, Pich, M, Hinzpeter, A, Uebelhack, R, Heinz, A, van Boemmel, F, Berg, T (2005). Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology 42, 793–798.
Sockalingam, S, Links, PS, Abbey, SE (2011). Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. Journal of Viral Hepatitis 18, 153–160.
Van Thiel, DH, Friedlander, L, Molloy, PJ, Fagiuoli, S, Kania, RJ, Caraceni, P (1995). Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. European Journal of Gastroenterology and Hepatology 7, 165–168.
Yee, HS, Chang, MF, Pocha, C, Lim, J, Ross, D, Morgan, TR, Monto, A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office (2012). Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. American Journal of Gastroenterology 107, 669–689.
Yovtcheva, SP, Rifai, MA, Moles, JK, Van Der Linden, BJ (2001). Psychiatric comorbidity among hepatitis-C-positive patients. Psychosomatics 42, 411–415.